Generate QR code
Open Access
Subscription Access
Extracorporeal methods of hemocorrection in kidney diseases (literature review)
https://doi.org/10.36485/1561-6274-2024-28-4-9-21
EDN: QUMKLQ
Abstract
The literature review is devoted to methods of extracorporeal hemocorrection, such as plasma exchange, cascade plasma filtration and immunosorption in kidney diseases, including glomerulonephritis associated with antibodies to the glomerular basement membrane, antineutrophil cytoplasmic antibodies-associated glomerulonephritis, focal segmental glomerulosclerosis, systemic lupus erythematosus, atypical hemolytic-uremic syndrome in adults
About the Author
A. M. Fomin
Moscow Regional Research Clinical Institute named after M.F. Vladimirsky
Russian Federation
Russian Federation
Prof. Aleksander M.Fomin, MD, PhD, DMedSci, Department of Surgical Hemocorrection and Detoxification, senior researcher
120110, Russia, Moscow, Shchepkina St., 61/2, build. 9
References
1. Connelly-Smith L, Alquist CR, Aqui NA et al. Guidelines on the use of therapeutic apheresis in clinical practice – evidencebased approach from th writing committee of the American Society for Apheresis: the Ninth special issue. J Clin Apher 2023;38:77– 278. doi: 10.1002/jca.22043
2. Williams ME, Balogun RA. Principles of separation:indications and therapeutic targets for plasma exchange. Clin J Am Soc Nephrol 2014;9(1):181–190. doi: 10.2215/CJN.04680513
3. Pusey CD, Levy JB. Plasmapheresis in immunologic renal disease. Blood Purif 2012;33(1-3):190–198. doi: 10.1159/000334155
4. Hafer C, Golla P, Gericke M et al. Membrane versus centrifuge-based therapeutic plasma exchange: a randomized prospective crossover study. Int UrolNephrol 2016;48(1):133–138. doi: 10.1007/s11255-015-1137-3
5. Yamaji K. Immunoadsorption for collagen and rheumatic diseases. Transfusion and Apheresis Science 2017;56(5):666– 670. doi: 10.1016/j.transci.2017.08.012
6. Hirano R, Namazuda K, Hirata N. Double filtration plasmapheresis: review of current clinical applications. Ther Apher Dial 2021;25(2):145–151. doi: 10.1111/1744-9987.13548
7. Poullin P, Announ N, Mugnier B et al. Protein A-immunoadsorption (prosorba col-umn) in the treatment of rheumatoid arthritis. Joint Bone Spine 2005;72(2):101–103. doi: 10.1016/j.jbspin.2004.02.009
8. Sokolov AA, Manuilov AS, Bardakov SN et al. Programmed immunoadsorption with regeneration of adsoption columns in the treatment of lupus nephritis. Modern Rheumatology Journal 2020;14(3):111–116. (In Russ.) doi: 10/14412/1996-7012-2020-3-111-116
9. New Columns. Brandbook. LLC «NPF Pocard». 16 p. Internet resource https://pocard.ru/wp-content/uploads/Broshures/1.%20Брендбук_новые_колонки.pdf (In Russ.)
10. Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65(1):1–11. doi: 10.1002/ art.37715. doi: 10.1002/art.37715
11. Kalluri R, Wilson CB, Weber M et al. Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and goodpasture syndrome. J Am Soc Nephrol 1995;6(4):1178–1185. doi: 10.1681/ASN.V641178
12. Levy JB, Hammad T, Coulthart A et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004;66(4):1535–1540. doi: 10.1111/j.15231755.2004.00917.x
13. Johnson JP, Moore J, Austin HA et al. Therapy of antiglomerular basement membrane antibody disease: Analysis of prognostic significance of clinical, pathologic and treatment factors. Med (United States) 1985;64(4):219–227. doi: 10.1097/00005792-198507000-00003
14. Kaewput W, Thongprayoon C, Boonpheng B et al. In patient burden and mortality of Goodpasture's syndrome in the United States:nationwide inpatient sample 2003–2014. J Clin Med 2020;9:455. doi: 10.3390/jcm9020455
15. Marques C, Carvelli J, Biard L et al. Prognostic Factors in Anti-glomerular Basement Mem-brane Disease: A Multicenter Study of 119 Patients. Front Immunol 2019;10. doi: 10.3389/fimmu.2019.01665
16. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001;134(11):1033–1042. doi: 10.7326/0003-4819-134-11200106050-00009
17. Rovin BH, Adler SG, Barratt J et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:753–779. doi: 10.1016/j.kint.2021.05.015
18. Lockwood CM, Boulton-Jones JM, Lowenthal RM et al. Recovery from goodpasture’s syndrome after immunosuppressive treatment and plasmapheresis. Br Med J 1975;2(5965):252–254. doi: 10.1136/bmj.2.5965.252
19. Savage CO, Pusey CD, Bowman C et al. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980–4. Br Med J (Clin Res Ed) 1986;292:301–304. doi: 10.1136/bmj.292.6516.301
20. Hu W, Liu Z, Ji D et al. Staphylococcal protein a immunoadsorption for goodpas-ture’s syndrome in four chinese patients. Journal of Nephrology 2006;19(3):312–317
21. Laczika K, Knapp S, Derfler K et al. Immunoadsorption in goodpasture’s syndrome. Am J Kidney Dis 2000;36(2):392–395. doi: 10.1053/ajkd.2000.8993
22. Biesenbach P, Kain R, Derfler K et al. Long-term outcome of anti-glomerular base-ment membrane antibody disease treated with immunoadsorption. PLoS One 2014;9(7):e103568. doi: 10.1371/journal.pone.0103568
23. Zhang Y-y, Tang Z, Chen D-M et al. Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with anti-glomerular basement membrane nephritis. BMC Nephrol 2014;15:128. doi: 10.1186/1471-2369-15-128
24. Beck LH, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361(1):11–21. doi: 10.1056/NEJMoa0810457
25. Tomas NM, Beck LH, Meyer-Schwesinger C et al. Thrombospondin type-1 do-main-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014;371(24):2277–2287. doi: 10.1056/NEJMoa1409354
26. Sethi S, Debiec H, Madden B et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int 2020;97(1):163–174. doi: 10.1016/j.kint.2019.09.014
27. Sethi S, Madden BJ, Debiec H et al. Exostosin 1/exostosin 2-associated membra-nous nephropathy. J Am Soc Nephrol 2019;30(6):1123–1136. doi: 10.1681/ASN.2018080852
28. Xu Z, Chen L, Xiang H et al. Advances in Pathogenesis of Idiopathic Membranous Nephropathy. Kidney Dis 2020:330–345. doi: 10.1159/00050770
29. Ponticelli C, Zucchelli P, Passerini P et al. A 10-year followup of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995;48(5):1600–1604. doi: 10.1038/ki.1995.453
30. Cattran DC, Appel GB, Hebert LA et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001;59(4):1484–1490. doi: 10.1046/j. 1523-1755.2001.0590041484.x
31. Beck L, Bomback AS, Choi MJ et al. KDOQI US commentary on the 2012 KDI-GO clinical practice guideline for glomerulonephritis. Am J Kidney Dis 2013;62(3):403–441. doi: 10.1053/j.ajkd.2013.06.002
32. Perna A, Schieppati A, Zamora J et al. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis 2004;44(3):385–401. doi: 10.1053/j.ajkd.2004.05.020
33. Muller-Deile J, Schiffer L, Hiss M et al. A new rescue regimen with plasma ex-change and rituximab in high-risk membranous glomerulonephritis. Eur J Clin Invest 2015;45(12):1260– 1269. doi: 10.1111/eci.12545
34. Esnault VL, Besnier D, Testa A et al. Effect of protein a immunoadsorption in ne-phrotic syndrome of various etiologies. J Am Soc Nephrol 1999;10(9):2014–2017. doi: 10.1681/ASN.V1092014
35. Hamilton P, Kanigicherla D, Hanumapura P et al. Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti-PLA2 R positive prima-ry membranous nephropathy. J Clin Apher 2018;33(3):283–290. doi: 10.1002/jca.21599
36. Eskandary F, Wahrmann M, Biesenbach P et al. ABO antibody and complement depletion by immunoadsorption combined with membrane filtration a randomized, con-trolled, cross-over trial. Nephrol Dial Transplant 2014;29(3):706–714. doi: 10.1093/ndt/gft502
37. Weinmann-Menke J, Holtz S, Sollinger D et al. Treatment of membranous nephropa-thy in patients with THSD7A antibodies using immunoadsorption. Am J Kidney Dis 2019;74(6):849–852. doi: 10.1053/j.ajkd.2019.05.021
38. Konigshausen E, Sellin L. Circulating permeability factors in primary focal segmental glomerulosclerosis: areview of proposed candidates. Biomed Res Int 2016;2016:3765608. doi: 10.1155/2016/3765608
39. Kashgary A, Sontrop J, Li L et al. The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: a systematic review and meta-analysis of 77 case-reports and case-series. BMC Nephrology 2016;17:104. doi: 10.1186/s12882-016-0322-7
40. Ren H, Shen P, Li X et al. Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized con-trolled trial. Am J Nephrol 2013;37(1):84–90. doi: 10.1159/000346256
41. Beer A, Mayer G, Kronbichler A. Treatment strategies of adult primary focal seg-mental glomerulosclerosis: a systematic review focusing on the last two decades. Biomed Res Int 2016;2016:4192578. doi: 10.1155/2016/4192578
42. Lau EW, Ma PH, Wu X et al. Mycophenolate mofetil for pri mary focal segmental glomerulosclerosis: systematic review. Ren Fail 2013;35(6):914–929. doi: 10.3109/0886022X.2013.794687
43. Hansrivijit P, Cheungpasitporn W, Thongprayoon C et al. Rituximab therapy for fo-cal segmental glomerulosclerosis and minimal change disease in adults: a systematic re-view and meta-analysis. BMC Nephrol 2020;21(1):134. doi: 10.1186/s12882-020-01797-7
44. Korbet SM. The treatment of primary focal segmental glomerulosclerosis. Ren Fail 2000;22(6):685–696. doi: 10.1081/jdi-100101956
45. Mitwalli AH. Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis? Nephrol Dial Transplant 1998;13(6):1524–1528. doi: 10.1093/ndt/13.6.1524
46. Moriconi L, Lenti C, Puccini R et al. Proteinuria in focal segmental glomerulosclero-sis: role of circulating factors and therapeutic approach. Ren Fail 2001;23(3-4):533–541. doi: 10.1081/jdi-100104735
47. Muso E, Mune M, Hirano T et al. A prospective observational survey on the long-term effect of LDL apheresis on drugresistant nephrotic syndrome. Nephron Extra 2015;5(2):58–66. doi: 10.1159/000437338
48. Dirim AB, Demir E, Guller N et al. Efficacy of intravenous combined immunosuppression with plasmapheresis in adult patients with refractory primary focal segmental glomerulosclerosis. J Clin Apher 2022;37:376–387. doi: 10.1002/jca.21985
49. Fencl F, Vondrak K, Rosik T et al. Recurrence of nephrotic proteinuria in children with focal segmental glomoerulosclerosis: early treatment with plasmapheresis and immunoasorption should be associated with better prognosis. Minerva Pediatrica 2016;68:348–335
50. Uffing A, Perez-Saez MJ, Mazzali M et al. Recurrence of FSGS after kidney transplantation in adults. Clin J Am Soc Nephrol 2020;15:247–325. doi: 10.2215/CJN.08970719
51. Raina R, Krishnappa V, Sanchez-Kazi C et al. Dextransulfate plasma adsorption lipoprotein apheresis in drug resistant primary focal segmental glomerulosclerosis patients: results from a prospective, multicenter, single-arm intervention study. Front Pediatr 2019;7:454. doi: 10.3389/fped.2019.00454
52. Nakazawa D, Masuda S, Tomaru U et al. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol 2019;15(2):91–101. doi: 10.1038/s41584-018-0145-y
53. Yang JJ, Jennette JC, Falk RJ. Immune complex glomerulonephritis is induced in rats immunized with heterologous myeloperoxidase. Clin Exp Immunol 1994;97(3):466–473. doi: 10.1111/j.1365-2249.1994.tb06111.x
54. Pusey CD, Rees AJ, Evans DJ et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991;40:757–763. doi: 10.1038/ki.1991.272
55. Jayne DR, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18(7):2180–2188. doi: 10.1681/ASN.2007010090
56. Walsh M, Casian A, Flossmann O et al. Long-term followup of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 2013;84:397–402. doi: 10.1038/ki.2013.131
57. Walsh M, Merkel PA, Peh CA et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis (PEXIVAS). N Engl J Med 2020;382(7):622–631. doi: 10.1056/NEJMoa1803537
58. Derebail VK, Falk RJ. ANCA-associated vasculitis – refining therapy with plasma exchange and glucocorticoids. N Engl J Med 2020;382:671–673. doi: 10.1056/NEJMe1917490
59. Walsh M, Collister D, Zeng L et al. The effects of plasma exchange inpatients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ 2022;376:e064604. doi: 10.1136/bmj-2021-064604
60. Bellos I, Michelakis I, Nikolopoulos D. The role of plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Clinical Rheumatology 2020;40(4):1447– 1456. doi: 10.1007/s10067-020-05390-z
61. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases, translation into Russian. Bobkova IN, Bulanov NM, Zakharova EV et al., edited by EV Zakharova. Nephrologу and Dialуsis 2022;24(4):577–874 (In Russ.)
62. Palmer A, Cairns T, Dische F et al. Treatment of rapidly progressive glomerulone-phritis by extracorporeal immunoadsorption, prednisolone and cyclophosphamide. Nephrol Dial Transplant 1991;6(8):536–542. doi: 10.1093/ndt/6.8.536
63. Esnault VL, Testa A, Jayne DR et al. Influence of immunoadsorption on the removal of immunoglobulin G autoantibodies in crescentic glomerulonephritis. Nephron 1993;65:180–184. doi: 10.1159/000187471
64. Matic G, Michelsen A, Hofmann D et al. Three Cases of C-ANCA-Positive Vasculitis Treated with Immunoadsorption: Possible Benefit in Early Treatment. Therapeutic Apheresis and Dialysis 2001;5(1):68–72. doi: 10.1046/j.1526-0968.2001.005001068.x
65. Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol 2018;13(2):300–317
66. Soejima K, Mimura N, Hirashima M et al. A novel human metalloprotease synthe-sized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem 2001;130(4):475–480. doi: 10.1093/oxfordjournals.jbchem.a003009
67. Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopa-thies across Japan: database of Nara medical university during 1998 – 2008. Intern Med 2010;49(1):7–15. doi: 10.2169/internalmedicine.49.2706
68. Scully M, Hunt BJ, Benjamin S et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012;158(3):323–335. doi: 10.1111/j.1365-2141.2012.09167.x
69. Sarode R, Bandarenko N, Brecher ME et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher 2014;29(3):148–167. doi: 10.1002/jca.21302
70. Rock GA, Shumak KH, Buskard NA et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325(6):393–397. doi: 10.1056/NEJM199108083250604
71. Coppo P, Bussel A, Charrier S et al. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore) 2003;82:27–38. doi: 10.1097/00005792200301000-00003
72. Raval JS, Mazepa MA, Rollins-Raval MA et al. Therapeutic plasma exchange taper does not decrease exacerbations in immune thrombotic thrombocytopenic purpura patients. Transfusion 2020;60:1676–1680. doi: 10.1111/trf.15901
73. van Dorland HA, Taleghani MM, Sakai K et al. The international hereditary throm-botic thrombocytopenic purpura registry: key findings at enrollment until 2017. Haematologica 2019;104(10):2107–2115. doi: 10.3324/haematol.2019.216796
74. Cataland SR, Kourlas PJ, Yang S et al. Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura Blood Adv 2017;1(23):2075–2082. doi: 10.1182/bloodadvances.2017009308
75. Scully M, Cataland SR, Peyvandi F et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019;380(4):335–346. doi: 10.1056/NEJMoa1806311
76. Knobl P, Haas M, Laczika K et al. Immunoadsorption for the treatment of a patient with severe thrombotic thrombocytopenic purpura resistant to plasma exchange: kinetics of an inhibitor of ADAMTS13. J Thromb Haemost 2003;1(1):187–189. doi: 10.1046/j.1538-7836.2003.00004.x
77. Drew MJ. Resolution of refractory, classic thrombotic thrombocytopenic purpura af-ter staphylococcal protein a immunoadsorption. Transfusion 1994;34(6):536–538. doi: 10.1046/j.1537-2995.1994.34694295072.x
78. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005;365(9464):1073–1086. doi: 10.1016/S01406736(05)71144-2
79. Syed S, Hakala P, Singh AK et al. Role of pneumococcal NanA neuraminidase activity in peripheral blood. Front Cell Infect Microbiol 2019;9:218. doi: 10.3389/fcimb.2019.00218
80. Nathanson S, Kwon T, Elmaleh M et al. Acute neurological involvement in diarrhea associ[ated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2010;5:1218–1228. doi: 10.2215/CJN.08921209
81. Menne J, Nitschke M, Stingele R et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012;345:e4565. doi: 10.1136/bmj.e4565
82. Waters AM, Kerecuk L, Luk D et al. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience. J Pediatr 2007;151:140–144. doi: 10.1016/j.jpeds.2007.03.055.
83. Greinacher A, Friesecke S, Abel P et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4associated haemolytic uraemic syndrome: a prospective trial. Lancet 2011;378(9797):1166–1173. doi: 10.1016/S01406736(11)61253-1
84. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009;361(17):1676–1687. doi: 10.1056/ NEJMra0902814
85. Formeck C, Swiatecka-Urban A. Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol 2018;34:1337–1348. doi: 10.1007/s00467-018-4039-7
86. Fremeaux-Bacchi V, Miller EC, Liszewski MK et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008;112(13):4948–4952. doi: 10.1182/blood-2008-01-133702
87. Delvaeye M, Noris M, De Vriese A et al. Thrombomodulin mutations in atypical hemolyticuremic syndrome. N Engl J Med 2009;361(4):345–357. doi: 10.1056/NEJMoa0810739
88. Jozsi M, Licht C, Strobel S et al. Factor H autoantibodies in atypical hemolytic ure-mic syndrome correlate with CFHR1/ CFHR3 deficiency. Blood 2008;111(3):1512–1514. doi: 10.1182/blood-2007-09-109876
89. Bayer G, von Tokarski F, Thoreau B et al. Etiologyand outcomes of thrombotic mi-croangiopathies. CJASN 2019;14(4):557– 566. doi: 10.2215/CJN.11470918
90. Fakhouri F, Hourmant M, Campistol JM et al. Terminal complement inhibitor eculi-zumab in adultpatients with atypical hemolytic uremic syndrome: a Single-Arm, OpenLabel trial. Am J Kidney Dis 2016;68(1):84–93. doi: 10.1053/j.ajkd.2015.12.034
91. Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormali-ties in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010;5(10):1844–1859. doi: 10.2215/CJN.02210310
92. Cao M, Leite BN, Ferreiro T et al. Eculizumab modifies outcomes in adults with atypical hemolytic uremic syndrome with acute kidney injury. Am J Nephrol 2018;48(3):225–233. doi: 10.1159/000492865
93. Bobrova LA, Vatazin AV, Demyanova KA et al. Atipichnii gemolitiko_uremicheskii sindrom» Klinicheskie rekomendacii, 2021. (In Russ.) https://cr.minzdrav.gov.ru/recomend/550_2
94. Mannik M, Merrill CE, Stamps LD et al. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J Rheumatol 2003; 30(7):1495–1504
95. Hohenstein B, Bornstein SR, Aringer M. Immunoadsorption for connective tissue disease. Atheroscler Suppl 2013;14(1):185. doi: 10.1016/j.atherosclerosissup.2012.10.034
96. Jones JV, Cumming RH, Bucknall RC et al. Plasmapheresis in the management of acute systemic lupus erythematosus? Lancet 1976;1(7962):709–711. doi: 10.1016/s0140-6736(76)93088-9
97. Lewis EJ, Hunsicker LG, Lan SP et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The lupus nephritis collaborative study group. N Engl J Med 1992;326(21):1373– 1379. doi: 10.1056/NEJM199205213262101
98. Aringer M, Smolen JS, Graninger WB. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheumat 1998;41(3):414–420
99. Soyuoz A, Karadag O, Karaagac T et al. Therapeutic plasma exchange for refracto-ry SLE: a comparison of outcomes between different sub-phenotypes. Eur J Rheumatol 2018;5(1):32–36. doi: 10.5152/eurjrheum.2017.17088
100. Li QY, Yu F, Zhou FD, Zhao MH. Plasmapheresis Is Associated With Better Renal Outcomes in Lupus Nephritis Patients With Thrombotic Microangiopathy: A Case Series Study. Medicine (Baltimore) 2016;95:e3595. doi: 10.1097/MD.0000000000003595
101. Gordon C, Amissah-Arthur MB, Gayed M et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology 2018;57:e1– e45. doi: 10.1093/rheumatology/kex286
102. Federalnie klinicheskie rekomendacii po diagnostike i lecheniyu sistemnoi krasnoi volchanki. Associaciya revmatologov Rossii. 2016 g. – 24s (In Russ.) Internet resurs_https://rheumatolog.ru/sites/default/files/Pdf/clinrec/sistemnaya_krasnaya_volchanka_doc
103. Neuwelt CM. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial 2003;7:173–182. doi: 10.1046/j.1526-0968.2003.00032.x
104. Fanouriakis A, Kostopoulou M, Cheema K et al. 2019 Update of the Joint European League Against Rheumatism and European Reanal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020;79:713–723. doi: 10.1136/annrheumdis-2020-216924
105. Stummvoll G, Aringer M, Handisurya A et al. Immunoadsorption in autoimmune diseases affecting the kidney. Semin Nephrol 2017;37(5):478–487. doi: 10.1016/j.semnephrol.2017.05.020
106. Stummvoll GH, Aringer M, Smolen JS et al. IgG immunoadsorption reduces sys-temic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis 2005;64(7):1015–1021. doi: 10.1136/ard.2004.029660
107. Gaubitz M, Seidel M, Kummer S et al. Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus. J Autoimmun 1998;11(5):495–501. doi: 10.1006/jaut.1998.0229
108. Yang M, Liao C, Zhu Q et al. Meta-analysis on the efficacy and safety of immunoadsorption for systemic lupus erythematosus among Chinese population. Clin Rheumatol 2020;39:3581–3592. doi: 10.1007/s10067-020-05156-7
Review
For citations:
Fomin A.M. Extracorporeal methods of hemocorrection in kidney diseases (literature review). Nephrology (Saint-Petersburg). 2024;28(4):9-21. (In Russ.) https://doi.org/10.36485/1561-6274-2024-28-4-9-21. EDN: QUMKLQ
Views:
151
Email this article 